AdAlta delivers positive Phase I Extension Study results - Tim Oldham, MD, Adalta Ltd 00:00:00

Share On Facebook Share On Twitter

Discuss encouraging outcomes from a Phase I extension study of their lead asset, AD-214, aimed at combating Idiopathic Pulmonary Fibrosis (IPF). This pivotal study assessed the target Phase II dose of AD-214 in healthy volunteers

Recent Videos